Product ID: SQMIG35A2237
Report ID:
SQMIG35A2237 |
Region:
Global |
Published Date: March, 2024
Pages:
219
|
Tables:
59 |
Figures:
75
In March 2024, Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.
In March 2024, UK diagnostics firm 52North Health announced that it is preparing to launch on the British, American, and European markets next year a test for neutropenic sepsis, a condition that often occurs in cancer patients receiving chemotherapy that can be fatal if not treated immediately.
In December 2023, Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced it has raised $84 million in Series C funding for transformative sepsis diagnostic tool, led by Norwest Venture Partners with participation by additional new investors Sands Capital and Global Health Investment Corporation (GHIC).
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Product ID: SQMIG35A2237